keyword
MENU ▼
Read by QxMD icon Read
search

Brivaracetam

keyword
https://www.readbyqxmd.com/read/28600961/uplc-ms-ms-assay-for-identification-and-quantification-of-brivaracetam-in-plasma-sample-application-to-pharmacokinetic-study-in-rats
#1
Muzaffar Iqbal, Essam Ezzeldin, Khalid A Al-Rashood
Brivaracetam (BVR) is a novel antiepileptic drug (AED), approved clinically for the treatment of partial onset seizures in adults and adolescents. It has some abuse potential and assigned to Schedule V category under the Controlled Substance Act by the Drug Enforcement Administration. Being an AED and drug of abuse, a sensitive and robust assay is necessary for determination of BVR in biological fluids. Herein, we report a sensitive and validated UPLC-MS/MS assay for identification and quantification of BVR in plasma samples...
June 4, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/28597912/acute-and-long-term-effects-of-brivaracetam-and-brivaracetam-diazepam-combinations-in-an-experimental-model-of-status-epilepticus
#2
Jerome Niquet, Lucie Suchomelova, Kerry Thompson, Henrik Klitgaard, Alain Matagne, Claude Wasterlain
OBJECTIVE: To evaluate acute and long-term effects of intravenous brivaracetam (BRV) and BRV + diazepam (DZP) combination treatment in a rat model of self-sustaining status epilepticus (SSSE). METHODS: Rats were treated with BRV (10 mg/kg) 10 min after initiation of perforant path stimulation (PPS) as early treatment; or BRV (10-300 mg/kg), DZP (1 mg/kg), or BRV (0.3-10 mg/kg) + DZP (1 mg/kg) 10 min after the end of PPS (established SSSE). Seizure activity was recorded electrographically for 24 h posttreatment (acute effects), and for 1 week at 6-8 weeks or 12 months' posttreatment (long-term effects)...
June 9, 2017: Epilepsia
https://www.readbyqxmd.com/read/28596441/brivaracetam-and-levetiracetam-dose-adjustments-leading-to-behavioural-adverse-effects
#3
May Yung Tiet, Jithin George
No abstract text is available yet for this article.
June 8, 2017: Postgraduate Medical Journal
https://www.readbyqxmd.com/read/28587680/in-vitro-antineoplastic-effects-of-brivaracetam-and-lacosamide-on-human-glioma-cells
#4
Ambra Rizzo, Sara Donzelli, Vita Girgenti, Andrea Sacconi, Chiara Vasco, Andrea Salmaggi, Giovanni Blandino, Marta Maschio, Emilio Ciusani
BACKGROUND: Epilepsy is a frequent symptom in patients with glioma. Although treatment with antiepileptic drugs is generally effective in controlling seizures, drug-resistant patients are not uncommon. Multidrug resistance proteins (MRPs) and P-gp are over-represented in brain tissue of patients with drug-resistant epilepsy, suggesting their involvement in the clearance of antiepileptic medications. In addition to their anticonvulsant action, some drugs have been documented for cytotoxic effects...
June 6, 2017: Journal of Experimental & Clinical Cancer Research: CR
https://www.readbyqxmd.com/read/28501260/erratum-to-efficacy-and-tolerability-of-adjunctive-brivaracetam-in-patients-with-prior-antiepileptic-drug-exposure-a-post-hoc-study-epilepsy-res-131-2017-70-75
#5
Ali A Asadi-Pooya, Michael R Sperling, Steve Chung, Pavel Klein, Anyzeila Diaz, Sami Elmoufti, Jimmy Schiemann, John Whitesides
No abstract text is available yet for this article.
May 10, 2017: Epilepsy Research
https://www.readbyqxmd.com/read/28492297/recent-anti-seizure-medications-in-the-intensive-care-unit
#6
Cindy Orinx, Benjamin Legros, Nicolas Gaspard
BACKGROUND: Seizures and status epilepticus (SE), both clinical and subclinical, are frequent in critically ill patients. The list of available anti-seizure medications (ASMs) is expanding and now includes older and widely used drugs as well as more recent medications with a better safety and pharmacokinetics profile. METHODS: We review a selection of recent publications about the indications and administration of ASMs in critical care for the prophylaxis and treatment of seizures and SE, focusing on recent ASMs available as intravenous formulation and emphasizing pharmacokinetics and safety issues in relation to several aspects of critical illness...
May 11, 2017: Minerva Anestesiologica
https://www.readbyqxmd.com/read/28480518/postmarketing-experience-with-brivaracetam-in-the-treatment-of-epilepsies-a-multicenter-cohort-study-from-germany
#7
Isabel Steinig, Felix von Podewils, Gabriel Möddel, Sebastian Bauer, Karl Martin Klein, Esther Paule, Philipp S Reif, Laurent M Willems, Johann Philipp Zöllner, Rhina Kunz, Uwe Runge, Gerhard Kurlemann, Susanne Schubert-Bast, Felix Rosenow, Adam Strzelczyk
OBJECTIVE: To evaluate factors predicting efficacy, retention, and tolerability of add-on brivaracetam (BRV) in clinical practice. METHODS: A multicenter, retrospective cohort study recruiting all patients who started BRV between February and November 2016 with observation time between 3 and 12 months. RESULTS: Of a total of 262 patients (mean age 40, range 5-81 years, 129 male) treated with BRV, 227 (87%) were diagnosed to have focal, 19 (7%) idiopathic generalized and 8 (3%) symptomatic generalized epilepsy, whereas 8 (3%) were unclassified...
May 8, 2017: Epilepsia
https://www.readbyqxmd.com/read/28427029/treatment-of-refractory-and-super-refractory-status-epilepticus-with-brivaracetam-a-cohort-study-from-two-german-university-hospitals
#8
Adam Strzelczyk, Isabel Steinig, Laurent M Willems, Philipp S Reif, Christian Senft, Martin Voss, Bernadette Gaida, Felix von Podewils, Felix Rosenow
PURPOSE: We aimed to ascertain the possible use of brivaracetam (BRV) as an option for treatment of status epilepticus (SE). METHODS: A review of medical records was carried out to detect BRV administration in SE patients treated in Frankfurt and Greifswald during the period February 2016 to January 2017. The primary outcome question concerned SE resolution after BRV initiation. RESULTS: During that period, BRV was started with eleven adult patients with SE...
May 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28394442/brivaracetam-an-adjunctive-treatment-for-partial-onset-seizures
#9
REVIEW
John A Kappes, William J Hayes, Joe D Strain, Debra K Farver
Brivaracetam is an analogue of levetiracetam that is Food and Drug Administration-approved for adjunctive treatment of partial-onset seizures in patients 16 years and older. In placebo-controlled trials adjunct brivaracetam demonstrated efficacy in reducing the frequency of seizures. The most commonly reported adverse effects are somnolence, dizziness, and fatigue. Clinical trials have evaluated brivaracetam for safety and efficacy in adjunctive treatment of partial-onset seizures in patients 16 years and older for up to 16 weeks...
April 10, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28378057/tolerability-of-new-antiepileptic-drugs-a-network-meta-analysis
#10
REVIEW
Gaetano Zaccara, Fabio Giovannelli, Filippo Sean Giorgi, Valentina Franco, Sara Gasparini, Umberto Benedetto
OBJECTIVE: The objective of this study was to perform a comparative assessment of tolerability of all licensed new antiepileptic drugs (AEDs) through a network meta-analysis (NMA) including all placebo-controlled double-blind clinical trials (RCTs) in all conditions in which these drugs have been tested. METHODS: NMA with a frequentist approach was used to compare proportions of patients withdrawing because of adverse events (AEs). Analyses were conducted for all therapeutic doses pooled and specifically for high therapeutic doses...
July 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28370224/do-antiepileptic-drugs-increase-the-risk-of-infectious-diseases-a-meta-analysis-of-placebo-controlled-studies
#11
Gaetano Zaccara, Fabio Giovannelli, Filippo Sean Giorgi, Valentina Franco, Sara Gasparini, Francesco Mandò Tacconi
AIMS: Experimental studies show that some antiepileptic drugs (AEDs) may modify natural immune defences, thus influencing the risk of developing infectious diseases. The aim of this meta-analysis was to explore whether AEDs as a class of drugs or singularly may increase risk of infectious diseases. METHODS: A meta-analysis of all randomized, double-blind, placebo-controlled trials (RCTs) investigating any AED in any condition was performed. All terms that could be coded in the System Organ Classes (SOCs) of infections and infestations using the Medical Dictionary for Regulatory Activities were recorded...
March 31, 2017: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28364655/real-life-experience-with-brivaracetam-in-101-patients-with-difficult-to-treat-epilepsy-a-monocenter-survey
#12
Bernhard J Steinhoff, Matthias Bacher, Iancu Bucurenciu, Barbara Hillenbrand, Tassanai Intravooth, Reinhold Kornmeier, Christoph Kurth, Jakob Stockinger, Anke M Staack
PURPOSE: To assess the efficiency of brivaracetam under real-world conditions in a tertiary referral epilepsy center. METHODS: We consecutively collected patients treated at our center with brivaracetam (BRV). After a minimum observation period of six months we retrospectively analyzed the efficiency of BRV. RESULTS: Data of 101 patients (mean age 42 years, range 18-81 years, 54 females,) were analyzed. The median number of antiepileptic drugs (AEDs) used prior to BRV was 10 (range 2-18)...
May 2017: Seizure: the Journal of the British Epilepsy Association
https://www.readbyqxmd.com/read/28355045/schedules-of-controlled-substances-placement-of-brivaracetam-into-schedule-v-final-rule
#13
(no author information available yet)
This final rule adopts without change an interim final rule with request for comments published in the Federal Register on May 12, 2016. The Drug Enforcement Administration is placing the substance brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also referred to as BRV; UCB-34714; Briviact) (including its salts) into schedule V of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act, as revised by the Improving Regulatory Transparency for New Medical Therapies Act which was signed into law on November 25, 2015...
March 9, 2017: Federal Register
https://www.readbyqxmd.com/read/28335772/production-of-s-2-aminobutyric-acid-and-s-2-aminobutanol-in-saccharomyces-cerevisiae
#14
Nora Weber, Anaëlle Hatsch, Ludivine Labagnere, Harald Heider
BACKGROUND: Saccharomyces cerevisiae (baker's yeast) has great potential as a whole-cell biocatalyst for multistep synthesis of various organic molecules. To date, however, few examples exist in the literature of the successful biosynthetic production of chemical compounds, in yeast, that do not exist in nature. Considering that more than 30% of all drugs on the market are purely chemical compounds, often produced by harsh synthetic chemistry or with very low yields, novel and environmentally sound production routes are highly desirable...
March 23, 2017: Microbial Cell Factories
https://www.readbyqxmd.com/read/28331468/will-brivaracetam-help-my-patient-only-time-will-tell
#15
Jacqueline French
No abstract text is available yet for this article.
January 2017: Epilepsy Currents
https://www.readbyqxmd.com/read/28293101/new-developments-in-the-management-of-partial-onset-epilepsy-role-of-brivaracetam
#16
REVIEW
Giangennaro Coppola, Giulia Iapadre, Francesca Felicia Operto, Alberto Verrotti
Currently, a number of novel anticonvulsant drugs, the so-called third generation, are in various stages of development. Several of them are already available or in ongoing clinical trials. These new compounds should take advantage of new insights into the basic pathophysiology of epileptogenesis, drug metabolism and drug interactions. Many of them still need to be further evaluated mainly in real-world observational trials and registries. Among newer anticonvulsant drugs for partial-onset seizures (POSs), rufinamide, lacosamide, eslicarbazepine and perampanel are those new treatment options for which more substantial clinical evidence is currently available, both in adults and, to some extent, in children...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28280887/brivaracetam-population-pharmacokinetics-in-children-with-epilepsy-aged-1%C3%A2-month-to-16%C3%A2-years
#17
Rik Schoemaker, Janet R Wade, Armel Stockis
PURPOSE: The aims of the study were to develop a population pharmacokinetic model of orally administered brivaracetam in paediatric patients and to provide dosing suggestions. METHODS: Analysis included 600 brivaracetam plasma concentrations from a phase 2a study (NCT00422422; N01263) in 96 paediatric patients with epilepsy aged 1 month to 16 years, taking one to three concomitant antiepileptic drugs (AEDs). Pharmacokinetic analysis was performed using non-linear mixed effects modelling, and a stepwise covariate search was used to determine factors influencing brivaracetam clearance...
June 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28279891/efficacy-and-tolerability-of-adjunctive-brivaracetam-in-patients-with-prior-antiepileptic-drug-exposure-a-post-hoc-study
#18
Ali A Asadi-Pooya, Michael R Sperling, Steve Chung, Pavel Klein, Anyzeila Diaz, Sami Elmoufti, Jimmy Schiemann, John Whitesides
Brivaracetam (BRV), a selective, high-affinity ligand for synaptic vesicle protein 2A, is a new antiepileptic drug (AED) for adjunctive treatment of focal (partial-onset) seizures in adults with epilepsy. This post-hoc analysis was conducted to explore the efficacy of adjunctive BRV in patients with prior levetiracetam (LEV) exposure and whether changes in efficacy were related to the similar mechanism of action of these two drugs. Data were pooled from three Phase III studies (NCT00490035; NCT00464269; NCT01261325) of adults with focal seizures taking 1-2 AEDs who received placebo or BRV 50-200mg/day without titration over a 12-week treatment period...
March 2017: Epilepsy Research
https://www.readbyqxmd.com/read/28236727/health-related-quality-of-life-in-double-blind-phase-iii-studies-of-brivaracetam-as-adjunctive-therapy-of-focal-seizures-a-pooled-post-hoc-analysis
#19
Christian Brandt, Simon Borghs, Sami Elmoufti, Knut Mueller, Rebecca Townsend, Christine de la Loge
PURPOSE: The effect of adjunctive brivaracetam on health-related quality of life (HRQoL) was assessed in a post-hoc analysis using pooled data from three randomized, double-blind, placebo-controlled Phase III studies in patients with refractory focal seizures (NCT00490035, NCT00464269, and NCT01261325). METHODS: The Patient-Weighted Quality of Life in Epilepsy Questionnaire (QOLIE-31-P) was completed at randomization, and weeks 4, 8 (in two of three studies), and 12 (end of the treatment period)...
April 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28220535/interaction-of-approved-drugs-with-synaptic-vesicle-protein-2a
#20
Azeem Danish, Vigneshwaran Namasivayam, Anke C Schiedel, Christa E Müller
Levetiracetam (LEV) and its recently approved derivative brivaracetam are anti-epileptic drugs with a unique mechanism of action. The synaptic vesicle protein 2A (SV2A) was previously identified as their main target. In the current study, we tested a collection of 500 approved drugs for interaction with the human SV2A protein expressed in Chinese hamster ovary cells. Competition binding studies were performed using cell lysates with high SV2A expression and [(3) H]brivaracetam as a radioligand. A hit rate of 3% was obtained, defined as compounds that inhibited radioligand binding by more than 90% at a screening concentration of 20 μM...
April 2017: Archiv der Pharmazie
keyword
keyword
110670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"